1. receipt of pooled immunoglobulin in past 30 days 2. current or prior enrollment in a sars-cov-2 antibody or t-cell therapeutic study. note: patients enrolled on other randomized controlled trials of pharmaceutical and/or non-pharmaceutical interventions for covid and meeting eligibility criteria will not be excluded, as determined by study pi (or designee) on a case-by-case basis and as allowed by eligibility criteria of the other trials. 3. contraindication to transfusion or history of prior reactions to transfusion blood products. this may include religious or cultural objections to receiving blood products and transfusions. 4. abo-compatible titered plasma is not available 5. \> 10 days from noted covid-related subjective or objective fever at randomization. patients without subjective or objective fever, \> 10 days from symptom onset as determined by study pi.

1. receipt of pooled immunoglobulin in past 30 days 2. current or prior enrollment in a sars-cov-2 antibody or t-cell therapeutic study. note: patients enrolled on other randomized controlled trials of pharmaceutical and/or non-pharmaceutical interventions for covid and meeting eligibility criteria will not be excluded, as determined by study pi (or designee) on a case-by-case basis and as allowed by eligibility criteria of the other trials. 3. contraindication to transfusion or history of prior reactions to transfusion blood products. this may include religious or cultural objections to receiving blood products and transfusions. 4. abo-compatible titered plasma is not available 5. \> 10 days from noted covid-related subjective or objective fever at randomization. patients without subjective or objective fever, \> 10 days from symptom onset as determined by study pi.

receipt of pooled immunoglobulin in past 30 days current or prior enrollment in a sars-cov-2 antibody or t-cell therapeutic study. note: patients enrolled on other randomized controlled trials of pharmaceutical and/or non-pharmaceutical interventions for covid and meeting eligibility criteria will not be excluded, as determined by study pi (or designee) on a case-by-case basis and as allowed by eligibility criteria of the other trials. contraindication to transfusion or history of prior reactions to transfusion blood products. this may include religious or cultural objections to receiving blood products and transfusions. abo-compatible titered plasma is not available > 10 days from noted covid-related subjective or objective fever at randomization. patients without subjective or objective fever, > 10 days from symptom onset as determined by study pi.

receipt of pooled immunoglobulin in past 30 days current or prior enrollment in a sars-cov-2 antibody or t-cell therapeutic study. note: patients enrolled on other randomized controlled trials of pharmaceutical and/or non-pharmaceutical interventions for covid and meeting eligibility criteria will not be excluded, as determined by study pi (or designee) on a case-by-case basis and as allowed by eligibility criteria of the other trials. contraindication to transfusion or history of prior reactions to transfusion blood products. this may include religious or cultural objections to receiving blood products and transfusions. abo-compatible titered plasma is not available > 10 days from noted covid-related subjective or objective fever at randomization. patients without subjective or objective fever, > 10 days from symptom onset as determined by study pi.

1. receipt of pooled immunoglobulin in past 30 days 2. current or prior enrollment in a sars-cov-2 antibody or t-cell therapeutic study. note: patients enrolled on other randomized controlled trials of pharmaceutical and/or non-pharmaceutical interventions for covid and meeting eligibility criteria will not be excluded, as determined by study pi (or designee) on a case-by-case basis and as allowed by eligibility criteria of the other trials. 3. contraindication to transfusion or history of prior reactions to transfusion blood products. this may include religious or cultural objections to receiving blood products and transfusions. 4. abo-compatible titered plasma is not available 5. > 10 days from noted covid-related subjective or objective fever at randomization. patients without subjective or objective fever, > 10 days from symptom onset as determined by study pi.

1. receipt of pooled immunoglobulin in past 30 days 2. current or prior enrollment in a sars-cov-2 antibody or t-cell therapeutic study. note: patients enrolled on other randomized controlled trials of pharmaceutical and/or non-pharmaceutical interventions for covid and meeting eligibility criteria will not be excluded, as determined by study pi (or designee) on a case-by-case basis and as allowed by eligibility criteria of the other trials. 3. contraindication to transfusion or history of prior reactions to transfusion blood products. this may include religious or cultural objections to receiving blood products and transfusions. 4. abo-compatible titered plasma is not available 5. > 10 days from noted covid-related subjective or objective fever at randomization. patients without subjective or objective fever, > 10 days from symptom onset as determined by study pi.